News Archive

GAITHERSBURG, Md., Aug. 24, 2020 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the first volunteers have been enrolled in the Phase 2 portion of its ongoing clinical trial to evaluate the immunogenicity and safety of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate. The Phase 2 clinical trial expands on the age range of the Phase 1 portion by including older adults 60-84 years of age as approximately 50 percent of the trial’s population. NVX‑CoV2373 is a stable, prefusion protein made using Novavax’ nanoparticle technology and includes Novavax’ proprietary Matrix‑M™ adjuvant.

The OrganoPlate® Graft is the first in vitro cell culture platform that allows vascularization of 3D tissues like spheroids, organoids, and tumors in vitro.

In this webinar, you will learn:

Limitations of current models How to build 3D vascularized tissues How to form vascular beds in vitro How to add 3D microtissues in the OrganoPlate Graft How to set up available assays How to get started in your lab

Image: https://go.mimetas.com

(Rockville, MD – August 20, 2020) –  Scheer Partners is proud to announce that 704 Quince Orchard Road, Gaithersburg, Maryland is 100% leased.

In 2018 Scheer Partners’ affiliate, South Duvall, part of a joint venture with a publicly traded REIT, acquired 704 Quince Orchard Road. 704 Quince Orchard Road presented an opportunity to convert an underperforming office building in the Gaithersburg Life Sciences Cluster. Scheer Partners, Inc. provided brokerage, construction management, and property management services for the 80,000 square foot project and made the entire building “lab-ready.” Scheer Partners’ Adnan Sheikh spearheaded construction management of the project in partnership with their Property Management Division, led by Ayesha Murray, which continues to ensure the building operates at peak performance.

GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced Mayo Clinic has committed $1.75M as a lead investor in a $7 million convertible note financing round.

Mayo Clinic is collaborating with APT to conduct a clinical trial using PhageBankTM investigational therapy to address the significant unmet need for alternative treatments for chronic infections following joint replacement (referred to as “periprosthetic joint infections,” or “PJIs”). Proceeds from the convertible note are designated to initiate the trial.

The cells that allow people to smell are a key entryway for the coronavirus, making nose coverings crucial, suggests new research from the Johns Hopkins University.

The nose already had been emerging as a main door for the virus and related respiratory disease. But this research specifically points to the olfactory cells because they have a very large number of receptors on their surface called ACE2 that have been shown to be vulnerable to coronaviruses.

The National Institute of Allergy and Infectious Diseases (NIAID) recently reissued the funding opportunity announcement (FOA) for the New Innovators Award (PAR-20-259). The first application due date is November 2, 2020. 

 The NIAID New Innovator Award supports a postdoctoral or newly independent Early Stage Investigator of exceptional creativity who proposes novel, original and insightful research concepts with the potential to produce a major impact, test scientific paradigms, or advance key concepts on broad, important problems in biomedical research of priority to NIAID. Applications proposing unexpected convergence of disciplines, new scientific directions, or the use of novel methodologies are encouraged. 

The University System of Maryland has partnered with Labster to provide its virtual laboratory simulations across all USM institutions. The university is working to integrate virtual science labs into its course offerings as the COVID-19 pandemic has limited students’ and instructors’ access to classrooms.

GAITHERSBURG, Md., Aug. 17, 2020 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the extension of the shelf life of NARCAN® (naloxone HCl) Nasal Spray from 24 months to 36 months. Narcan Nasal Spray was the first intranasal form of naloxone approved by FDA and Health Canada for the emergency treatment of known or suspected opioid overdose.